

**Supplemental Table S1.** UIC Except Insufficient Group for the Risk of PTC and PTMC According to Sex, BMI Levels, and Women's Menopausal Status Based on Exclusion of Insufficient Iodine Intake

	Controls	PTC	OR (95% CI) <sup>a</sup>	PTMC	OR (95% CI) <sup>a</sup>	Controls	PTC	OR (95% CI) <sup>a</sup>	PTMC	OR (95% CI) <sup>a</sup>
UIC, µg/gCr	Male (56 PTC, 50 PTMC <sup>b</sup> vs. 124 Controls) <sup>c</sup>									
85–219	59	4	1.00	7	1.00	140	6	1.00	16	1.00
≥220	49	52	13.74 (4.02–46.91)	42	6.41 (2.23–18.41)	215	147	21.11 (8.54–52.17)	171	8.88 (4.61–17.08)
UIC, µg/L	Female (153 PTC, 187 PTMC <sup>b</sup> vs. 376 Controls) <sup>c</sup>									
100–299	71	1	1.00	4	1.00	157	10	1.00	21	1.00
≥300	45	55	99.67 (9.88–982.18)	46	15.51 (4.58–52.50)	172	140	14.68 (7.12–30.24)	164	7.88 (4.40–14.11)
UIC, µg/gCr	BMI <25 kg/m <sup>2</sup> (145 PTC, 174 PTMC <sup>b</sup> vs. 326 Controls) <sup>c</sup>									
85–219	132	7	1.00	13	1.00	67	3	1.00	10	1.00
≥220	171	138	18.03 (7.70–42.21)	160	10.17 (5.04–20.50)	93	61	23.99 (5.82–98.74)	53	7.58 (2.65–21.66)
UIC, µg/L	BMI ≥ 25 kg/m <sup>2</sup> (64 PTC, 63 PTMC <sup>b</sup> vs. 174 Controls) <sup>c</sup>									
100–299	150	8	1.00	13	1.00	78	3	1.00	12	1.00
≥300	143	135	19.04 (8.62–42.07)	159	13.95 (6.92–28.12)	74	60	25.81 (6.64–100.31)	51	4.34 (1.86–10.16)
UIC, µg/gCr	Postmenopausal women (73 PTC, 72 PTMC <sup>b</sup> vs. 184 Controls) <sup>c</sup>									
85–219	76	4	1.00	11	1.00	64	2	1.00	5	1.00
≥220	100	76	27.58 (8.57–88.76)	104	9.18 (3.99–21.12)	115	71	17.57 (3.67–84.19)	67	6.05 (2.04–17.92)
UIC, µg/L	Premenopausal women (80 PTC, 115 PTMC <sup>b</sup> vs. 192 Controls) <sup>c</sup>									
100–299	82	4	1.00	12	1.00	75	6	1.00	9	1.00
≥300	87	75	24.89 (8.12–76.32)	103	9.84 (4.42–21.91)	85	65	8.94 (3.32–24.08)	61	5.66 (2.29–13.96)

UIC, urinary iodine concentration; PTC, papillary thyroid cancer; PTMC, papillary thyroid microcarcinoma; BMI, body mass index; OR, odds ratio; CI, confidence interval.

<sup>a</sup>Adjusted for age, sex, total energy intake, education level, family history of cancer, and each past history of dyslipidemia and benign thyroid disease; <sup>b</sup>PTMC with 5 mm ≤ tumor size <10 mm;<sup>c</sup>Total numbers of each category in the study population.